Truxima (rituximab) vs Idacio (adalimumab-aacf)
Truxima (rituximab) vs Idacio (adalimumab-aacf)
Truxima (rituximab) and Idacio (adalimumab-aacf) are both biologic medications used to treat various autoimmune conditions, but they work in different ways and are approved for different indications. Truxima targets CD20-positive B cells and is commonly used for conditions like non-Hodgkin's lymphoma and rheumatoid arthritis, whereas Idacio targets tumor necrosis factor-alpha (TNF-alpha) and is used for diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. The choice between Truxima and Idacio would depend on the specific condition being treated, the patient's medical history, and how their body has responded to previous treatments, so a healthcare provider's guidance is crucial in making the right decision.
Difference between Truxima and Idacio
| Metric | Truxima (rituximab) | Idacio (adalimumab-aacf) |
|---|---|---|
| Generic name | Rituximab | Adalimumab-aacf |
| Indications | Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis | Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and plaque psoriasis |
| Mechanism of action | Targets CD20-positive B lymphocytes and induces their cell death | Blocks tumor necrosis factor (TNF), thereby reducing inflammation |
| Brand names | Truxima, Rituxan, MabThera | Idacio, Humira |
| Administrative route | Intravenous infusion | Subcutaneous injection |
| Side effects | Infusion reactions, infections, body aches, fatigue, skin rashes | Infections, injection site reactions, headache, rash, nausea |
| Contraindications | Hypersensitivity to rituximab or any of its components, active severe infections | Hypersensitivity to adalimumab or any of its components, active tuberculosis or other severe infections |
| Drug class | Monoclonal antibody | Monoclonal antibody |
| Manufacturer | Celltrion Healthcare, Teva Pharmaceuticals, Genentech (Roche) | Fresenius Kabi |
Efficacy
Truxima (Rituximab) Efficacy in Rheumatoid Arthritis
Truxima, a biosimilar to the original rituximab biologic, is an effective treatment for rheumatoid arthritis (RA), particularly in patients who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies. Rituximab, the active ingredient in Truxima, is a monoclonal antibody that targets CD20-positive B cells, which are believed to play a role in the pathogenesis of RA. Clinical trials have demonstrated that rituximab can significantly reduce the signs and symptoms of RA and can improve physical function when used in combination with methotrexate.
In terms of efficacy, rituximab has been shown to reduce joint inflammation and slow the progression of joint damage. Patients treated with rituximab have reported improvements in disease activity scores (DAS28), which is a measure of RA disease activity. Additionally, rituximab has been associated with a reduction in the progression of joint damage as observed through radiographic analysis, which is a critical aspect of RA treatment as it relates to maintaining joint function over time.
Idacio (Adalimumab-aacf) Efficacy in Rheumatoid Arthritis
Idacio is a biosimilar to the reference product adalimumab and is indicated for the treatment of rheumatoid arthritis among other inflammatory conditions. Adalimumab-aacf works by inhibiting TNF, a substance in the body that causes inflammation in the joints, and is a key factor in the pathogenesis of RA. Clinical studies have shown that adalimumab can reduce the signs and symptoms of RA, induce major clinical response, inhibit the progression of structural damage, and improve physical function in adult patients with moderately to severely active RA.
The efficacy of adalimumab in RA has been well-established through extensive research and clinical trials. Patients receiving adalimumab have experienced significant improvements in both clinical response and physical function as measured by various validated scales such as the American College of Rheumatology (ACR) criteria for improvement in RA (ACR20, ACR50, ACR70). Furthermore, adalimumab has been shown to maintain long-term efficacy and safety profiles, making it a viable long-term treatment option for individuals with RA.
Regulatory Agency Approvals
Truxima
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Idacio
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Truxima or Idacio today
If Truxima or Idacio are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us